HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed.

AbstractBACKGROUND AND PURPOSE:
We recently demonstrated that C225 maintenance therapy after completion of radiotherapy further increased tumor radiocurability. The present study assessed mechanisms underlying the observed improvement in C225 efficacy in pre-irradiated tissue (tumor bed).
MATERIALS AND METHODS:
A431 xenografts growing in pre-irradiated and non-irradiated tissue were treated with C225. Tumors were assessed for growth delay, cell proliferation, hypoxia, EGFR and VEGF expressions. In vitro clonogenic survival of cells derived from these tumors was also assayed.
RESULTS:
Pre-irradiation of tumor bed induced growth retardation, reduction in Ki-67 labeling, and overexpression of HIF-1alpha, CA IX, EGFR and VEGF biomarkers. C225 treatment dramatically inhibited tumor growth in the irradiated tumor bed (P<0.0001), which was associated with further reduction in Ki-67 labeling, and reduced expression of HIF-1alpha, CA IX, EGFR and VEGF. Cells derived from tumors in the pre-irradiated bed showed increased sensitivity to C225. C225 was more cytotoxic against hypoxic than well-oxygenated A431 cells grown in vitro.
CONCLUSION:
A431 xenografts growing in pre-irradiated tumor bed exhibit enhanced sensitivity to C225. Pre-irradiated tissue microenvironment seems to render tumor cells more susceptible to C225 cytostatic and cytotoxic actions. If confirmed in other tumor models these findings support the use of C225 maintenance therapy after completion of radiotherapy.
AuthorsOliver Riesterer, Kathryn A Mason, Uma Raju, Qiuan Yang, Li Wang, Walter N Hittelman, K Kian Ang, Luka Milas
JournalRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Radiother Oncol) Vol. 92 Issue 3 Pg. 383-7 (Sep 2009) ISSN: 1879-0887 [Electronic] Ireland
PMID19695723 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • ErbB Receptors
  • Cetuximab
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology)
  • Antibodies, Monoclonal, Humanized
  • Apoptosis (drug effects, radiation effects)
  • Carcinoma, Squamous Cell (pathology, radiotherapy)
  • Cell Line, Tumor (drug effects, radiation effects)
  • Cell Proliferation (drug effects, radiation effects)
  • Cell Survival (drug effects)
  • Cetuximab
  • Disease Models, Animal
  • ErbB Receptors (antagonists & inhibitors, metabolism)
  • Humans
  • Immunohistochemistry
  • Male
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Neovascularization, Pathologic (prevention & control)
  • Probability
  • Radiation Tolerance (drug effects)
  • Transplantation, Heterologous
  • Tumor Cells, Cultured (drug effects, radiation effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: